BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -27.68 Million USD | -1.71% |
| 2022 | -27.21 Million USD | -176.76% |
| 2021 | 35.46 Million USD | 217.2% |
| 2020 | -30.25 Million USD | -36.25% |
| 2019 | -22.2 Million USD | -77.73% |
| 2018 | -12.49 Million USD | -69.49% |
| 2017 | -7.37 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.78 Million USD | -28.7% |
| 2024 Q2 | -9.72 Million USD | -43.33% |
| 2023 Q4 | -5.27 Million USD | -1280.1% |
| 2023 Q1 | -6.2 Million USD | -11.65% |
| 2023 FY | -27.68 Million USD | -1.71% |
| 2023 Q3 | -382 Thousand USD | 93.71% |
| 2023 Q2 | -6.07 Million USD | 2.17% |
| 2022 Q3 | -6.54 Million USD | 10.58% |
| 2022 FY | -27.21 Million USD | -176.76% |
| 2022 Q4 | -5.56 Million USD | 15.1% |
| 2022 Q2 | -7.32 Million USD | 5.93% |
| 2022 Q1 | -7.78 Million USD | 87.27% |
| 2021 Q2 | -7.3 Million USD | 15.78% |
| 2021 Q3 | 9.83 Million USD | 234.66% |
| 2021 Q4 | -61.13 Million USD | -721.77% |
| 2021 FY | 35.46 Million USD | 217.2% |
| 2021 Q1 | -8.67 Million USD | 83.15% |
| 2020 Q4 | -51.44 Million USD | -682.65% |
| 2020 Q3 | 8.83 Million USD | 238.1% |
| 2020 FY | -30.25 Million USD | -36.25% |
| 2020 Q1 | -5.96 Million USD | 68.47% |
| 2020 Q2 | -6.39 Million USD | -7.17% |
| 2019 Q1 | -93.1 Thousand USD | -489.69% |
| 2019 Q4 | -18.91 Million USD | -2956.7% |
| 2019 Q3 | -618.93 Thousand USD | -109.83% |
| 2019 FY | -22.2 Million USD | -77.73% |
| 2019 Q2 | -294.97 Thousand USD | -216.82% |
| 2018 Q1 | -1000.00 USD | 0.0% |
| 2018 Q3 | -650.00 USD | 0.0% |
| 2018 Q4 | -15.78 Thousand USD | -2329.08% |
| 2018 FY | -12.49 Million USD | -69.49% |
| 2017 FY | -7.37 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 13.257% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -190.87% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 32.294% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 46.678% |
| Azitra, Inc. | -7.61 Million USD | -263.492% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -237.828% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -303.437% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 4.508% |
| CEL-SCI Corporation | -31.47 Million USD | 12.044% |
| iBio, Inc. | -16.63 Million USD | -66.436% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -11.935% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -37.174% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | -16.49% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -97.034% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -453.368% |
| NanoViricides, Inc. | -8.51 Million USD | -225.09% |
| Oragenics, Inc. | -20.9 Million USD | -32.433% |
| BiomX Inc. | -27.68 Million USD | -0.0% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 364.675% |
| Palatin Technologies, Inc. | -22.49 Million USD | -23.066% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 34.134% |